Build Your Comparison

Side-by-side financial analysis
NYXH logo
NYXH
LIVN logo
LIVN
NVCR logo
NVCR
GKOS logo
GKOS
KO logo
KO
Try popular comparisons:

Stock Comparison

NYXH vs LIVN vs NVCR vs GKOS vs KO

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NYXH
Nyxoah S.A.

Medical - Instruments & Supplies

HealthcareNASDAQ • BE
Market Cap$52M
5Y Perf.-94.2%
LIVN
LivaNova PLC

Medical - Devices

HealthcareNASDAQ • GB
Market Cap$4.36B
5Y Perf.-6.5%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$2.02B
5Y Perf.-91.3%
GKOS
Glaukos Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$7.42B
5Y Perf.+34.7%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$355.61B
5Y Perf.+53.1%

NYXH vs LIVN vs NVCR vs GKOS vs KO — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NYXH logoNYXH
LIVN logoLIVN
NVCR logoNVCR
GKOS logoGKOS
KO logoKO
IndustryMedical - Instruments & SuppliesMedical - DevicesMedical - Instruments & SuppliesMedical - DevicesBeverages - Non-Alcoholic
Market Cap$52M$4.36B$2.02B$7.42B$355.61B
Revenue (TTM)$16M$1.43B$674M$551M$49.28B
Net Income (TTM)$-86M$107M$-173M$-189M$13.70B
Gross Margin48.3%67.5%75.2%78.1%61.7%
Operating Margin-5.3%13.4%-27.2%-15.6%29.3%
Forward P/E18.7x25.3x
Total Debt$42M$473M$290M$140M$45.49B
Cash & Equiv.$30M$636M$103M$91M$10.27B

NYXH vs LIVN vs NVCR vs GKOS vs KOLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NYXH
LIVN
NVCR
GKOS
KO
StockApr 21Jun 26Return
Nyxoah S.A. (NYXH)1005.8-94.2%
LivaNova PLC (LIVN)10093.5-6.5%
NovoCure Limited (NVCR)1008.7-91.3%
Glaukos Corporation (GKOS)100134.7+34.7%
The Coca-Cola Compa… (KO)100153.1+53.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: NYXH vs LIVN vs NVCR vs GKOS vs KO

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: KO leads in 3 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and dividend income and shareholder returns. LivaNova PLC is the stronger pick specifically for valuation and capital efficiency and recent price momentum and sentiment. NYXH and GKOS also each lead in at least one category. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇KO emerged as the overall leader. Track its performance:
NYXH
Nyxoah S.A.
The Growth Play

NYXH ranks third and is worth considering specifically for growth exposure.

  • Rev growth 121.6%, EPS growth -30.9%, 3Y rev CAGR 48.1%
  • 121.6% revenue growth vs KO's 1.9%
Best for: growth exposure
LIVN
LivaNova PLC
The Value Play

LIVN is the #2 pick in this set and the best alternative if value and momentum is your priority.

  • Lower P/E (18.7x vs 25.3x)
  • +70.3% vs NYXH's -81.6%
Best for: value and momentum
NVCR
NovoCure Limited
The Healthcare Pick

Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.

Best for: healthcare exposure
GKOS
Glaukos Corporation
The Income Pick

GKOS is the clearest fit if your priority is income & stability and long-term compounding.

  • beta 1.01
  • 379.3% 10Y total return vs KO's 121.1%
  • Lower volatility, beta 1.01, Low D/E 21.3%, current ratio 4.69x
  • Beta 1.01, current ratio 4.69x
Best for: income & stability and long-term compounding
KO
The Coca-Cola Company
The Quality Compounder

KO carries the broadest edge in this set and is the clearest fit for quality and dividends.

  • 27.8% margin vs NYXH's -5.3%
  • 2.5% yield; 56-year raise streak; the other 4 pay no meaningful dividend
  • 13.1% ROA vs NYXH's -80.8%, ROIC 15.8% vs -76.4%
Best for: quality and dividends
See the full category breakdown
CategoryWinnerWhy
GrowthNYXH logoNYXH121.6% revenue growth vs KO's 1.9%
ValueLIVN logoLIVNLower P/E (18.7x vs 25.3x)
Quality / MarginsKO logoKO27.8% margin vs NYXH's -5.3%
Stability / SafetyGKOS logoGKOSBeta 1.01 vs NVCR's 2.21, lower leverage
DividendsKO logoKO2.5% yield; 56-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)LIVN logoLIVN+70.3% vs NYXH's -81.6%
Efficiency (ROA)KO logoKO13.1% ROA vs NYXH's -80.8%, ROIC 15.8% vs -76.4%

NYXH vs LIVN vs NVCR vs GKOS vs KO — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

NYXHNyxoah S.A.

Segment breakdown not available.

LIVNLivaNova PLC
FY 2025
Cardiopulmonary Segment
57.0%$785M
Neuromodulation Segment
43.0%$593M
NVCRNovoCure Limited

Segment breakdown not available.

GKOSGlaukos Corporation
FY 2019
Glaucoma
97.5%$231M
Corneal Health
2.5%$6M
KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B

NYXH vs LIVN vs NVCR vs GKOS vs KO — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLKOLAGGINGNVCR

Income & Cash Flow (Last 12 Months)

KO leads this category, winning 3 of 6 comparable metrics.

KO is the larger business by revenue, generating $49.3B annually — 3020.2x NYXH's $16M. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to NYXH's -5.3%. On growth, NYXH holds the edge at +5.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricNYXH logoNYXHNyxoah S.A.LIVN logoLIVNLivaNova PLCNVCR logoNVCRNovoCure LimitedGKOS logoGKOSGlaukos Corporati…KO logoKOThe Coca-Cola Com…
RevenueTrailing 12 months$16M$1.4B$674M$551M$49.3B
EBITDAEarnings before interest/tax-$81M$220M-$165M-$40M$15.5B
Net IncomeAfter-tax profit-$86M$107M-$173M-$189M$13.7B
Free Cash FlowCash after capex-$73M$161M-$48M-$18M$12.6B
Gross MarginGross profit ÷ Revenue+48.3%+67.5%+75.2%+78.1%+61.7%
Operating MarginEBIT ÷ Revenue-5.3%+13.4%-27.2%-15.6%+29.3%
Net MarginNet income ÷ Revenue-5.3%+7.5%-25.7%-34.3%+27.8%
FCF MarginFCF ÷ Revenue-4.5%+11.2%-7.1%-3.4%+25.5%
Rev. Growth (YoY)Latest quarter vs prior year+5.9%+14.3%+12.3%+41.2%+12.1%
EPS Growth (YoY)Latest quarter vs prior year+38.3%+106.7%-100.0%-6.3%+18.2%
KO leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

LIVN leads this category, winning 3 of 6 comparable metrics.

On an enterprise value basis, LIVN's 17.4x EV/EBITDA is more attractive than KO's 26.4x.

MetricNYXH logoNYXHNyxoah S.A.LIVN logoLIVNLivaNova PLCNVCR logoNVCRNovoCure LimitedGKOS logoGKOSGlaukos Corporati…KO logoKOThe Coca-Cola Com…
Market CapShares × price$52M$4.4B$2.0B$7.4B$355.6B
Enterprise ValueMkt cap + debt − cash$66M$4.2B$2.2B$7.5B$390.8B
Trailing P/EPrice ÷ TTM EPS-0.51x-17.84x-14.57x-38.66x27.18x
Forward P/EPrice ÷ next-FY EPS est.18.68x25.27x
PEG RatioP/E ÷ EPS growth rate2.43x
EV / EBITDAEnterprise value multiple17.39x26.39x
Price / SalesMarket cap ÷ Revenue4.48x3.14x3.09x14.63x7.42x
Price / BookPrice ÷ Book value/share0.93x3.61x5.82x11.05x10.40x
Price / FCFMarket cap ÷ FCF25.18x67.15x
LIVN leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

KO leads this category, winning 6 of 9 comparable metrics.

KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-164 for NYXH. GKOS carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to KO's 1.33x. On the Piotroski fundamental quality scale (0–9), KO scores 7/9 vs NYXH's 2/9, reflecting strong financial health.

MetricNYXH logoNYXHNyxoah S.A.LIVN logoLIVNLivaNova PLCNVCR logoNVCRNovoCure LimitedGKOS logoGKOSGlaukos Corporati…KO logoKOThe Coca-Cola Com…
ROE (TTM)Return on equity-164.4%+9.1%-50.8%-26.5%+41.1%
ROA (TTM)Return on assets-80.8%+4.2%-16.5%-20.1%+13.1%
ROICReturn on invested capital-76.4%+11.5%-16.4%-9.2%+15.8%
ROCEReturn on capital employed-80.4%+10.2%-28.9%-10.3%+17.3%
Piotroski ScoreFundamental quality 0–925537
Debt / EquityFinancial leverage0.86x0.39x0.85x0.21x1.33x
Net DebtTotal debt minus cash$12M-$162M$187M$49M$35.2B
Cash & Equiv.Liquid assets$30M$636M$103M$91M$10.3B
Total DebtShort + long-term debt$42M$473M$290M$140M$45.5B
Interest CoverageEBIT ÷ Interest expense-32.73x5.18x-96.80x-18.69x10.70x
KO leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

GKOS leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in KO five years ago would be worth $16,560 today (with dividends reinvested), compared to $515 for NYXH. Over the past 12 months, LIVN leads with a +70.3% total return vs NYXH's -81.6%. The 3-year compound annual growth rate (CAGR) favors GKOS at 23.7% vs NYXH's -44.0% — a key indicator of consistent wealth creation.

MetricNYXH logoNYXHNyxoah S.A.LIVN logoLIVNLivaNova PLCNVCR logoNVCRNovoCure LimitedGKOS logoGKOSGlaukos Corporati…KO logoKOThe Coca-Cola Com…
YTD ReturnYear-to-date-69.1%+30.9%+35.5%+14.5%+20.3%
1-Year ReturnPast 12 months-81.6%+70.3%-2.3%+29.9%+17.2%
3-Year ReturnCumulative with dividends-82.4%+65.4%-59.8%+89.5%+47.0%
5-Year ReturnCumulative with dividends-94.9%-2.8%-91.9%+57.4%+65.6%
10-Year ReturnCumulative with dividends-94.2%+62.7%+62.1%+379.3%+121.1%
CAGR (3Y)Annualised 3-year return-44.0%+18.3%-26.2%+23.7%+13.7%
GKOS leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — LIVN and KO each lead in 1 of 2 comparable metrics.

KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than NVCR's 2.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LIVN currently trades 98.3% from its 52-week high vs NYXH's 16.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricNYXH logoNYXHNyxoah S.A.LIVN logoLIVNLivaNova PLCNVCR logoNVCRNovoCure LimitedGKOS logoGKOSGlaukos Corporati…KO logoKOThe Coca-Cola Com…
Beta (5Y)Sensitivity to S&P 5002.10x1.23x2.21x1.01x-0.20x
52-Week HighHighest price in past year$8.59$80.73$18.92$148.11$84.04
52-Week LowLowest price in past year$1.26$41.02$9.82$73.16$65.35
% of 52W HighCurrent price vs 52-week peak+16.2%+98.3%+94.0%+85.6%+98.3%
RSI (14)Momentum oscillator 0–10025.869.457.151.460.6
Avg Volume (50D)Average daily shares traded189K727K1.5M859K12.7M
Evenly matched — LIVN and KO each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: NYXH as "Buy", LIVN as "Buy", NVCR as "Buy", GKOS as "Buy", KO as "Buy". Consensus price targets imply 331.7% upside for NYXH (target: $6) vs -0.2% for LIVN (target: $79). KO is the only dividend payer here at 2.46% yield — a key consideration for income-focused portfolios.

MetricNYXH logoNYXHNyxoah S.A.LIVN logoLIVNLivaNova PLCNVCR logoNVCRNovoCure LimitedGKOS logoGKOSGlaukos Corporati…KO logoKOThe Coca-Cola Com…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyBuy
Price TargetConsensus 12-month target$6.00$79.25$33.50$149.00$86.13
# AnalystsCovering analysts514152448
Dividend YieldAnnual dividend ÷ price+2.5%
Dividend StreakConsecutive years of raises56
Dividend / ShareAnnual DPS$2.04
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.1%0.0%0.0%+0.2%
Insufficient data to determine a leader in this category.
Key Takeaway

KO leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). LIVN leads in 1 (Valuation Metrics). 1 tied.

Best OverallThe Coca-Cola Company (KO)Leads 2 of 6 categories
Loading custom metrics...

NYXH vs LIVN vs NVCR vs GKOS vs KO: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is NYXH or LIVN or NVCR or GKOS or KO a better buy right now?

For growth investors, Nyxoah S.

A. (NYXH) is the stronger pick with 121. 6% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). The Coca-Cola Company (KO) offers the better valuation at 27. 2x trailing P/E (25. 3x forward), making it the more compelling value choice. Analysts rate Nyxoah S. A. (NYXH) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — NYXH or LIVN or NVCR or GKOS or KO?

On forward P/E, LivaNova PLC is actually cheaper at 18.

7x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — NYXH or LIVN or NVCR or GKOS or KO?

Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.

6%, compared to -94. 9% for Nyxoah S. A. (NYXH). Over 10 years, the gap is even starker: GKOS returned +379. 3% versus NYXH's -94. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — NYXH or LIVN or NVCR or GKOS or KO?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus NovoCure Limited's 2. 21β — meaning NVCR is approximately -1202% more volatile than KO relative to the S&P 500. On balance sheet safety, Glaukos Corporation (GKOS) carries a lower debt/equity ratio of 21% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

05

Which is growing faster — NYXH or LIVN or NVCR or GKOS or KO?

By revenue growth (latest reported year), Nyxoah S.

A. (NYXH) is pulling ahead at 121. 6% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: The Coca-Cola Company grew EPS 23. 6% year-over-year, compared to -483. 6% for LivaNova PLC. Over a 3-year CAGR, NYXH leads at 48. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — NYXH or LIVN or NVCR or GKOS or KO?

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -899. 1% for Nyxoah S. A. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -827. 8% for NYXH. At the gross margin level — before operating expenses — GKOS leads at 77. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is NYXH or LIVN or NVCR or GKOS or KO more undervalued right now?

On forward earnings alone, LivaNova PLC (LIVN) trades at 18.

7x forward P/E versus 25. 3x for The Coca-Cola Company — 6. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NYXH: 331. 7% to $6. 00.

08

Which pays a better dividend — NYXH or LIVN or NVCR or GKOS or KO?

In this comparison, KO (2.

5% yield) pays a dividend. NYXH, LIVN, NVCR, GKOS do not pay a meaningful dividend and should not be held primarily for income.

09

Is NYXH or LIVN or NVCR or GKOS or KO better for a retirement portfolio?

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Nyxoah S. A. (NYXH) carries a higher beta of 2. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, NYXH: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between NYXH and LIVN and NVCR and GKOS and KO?

These companies operate in different sectors (NYXH (Healthcare) and LIVN (Healthcare) and NVCR (Healthcare) and GKOS (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NYXH is a small-cap high-growth stock; LIVN is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; GKOS is a small-cap high-growth stock; KO is a large-cap quality compounder stock. KO pays a dividend while NYXH, LIVN, NVCR, GKOS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.